What is it about?
The synthesized compound PSHA contains in its molecule two pharmacophores: N-hydroxybutanamide and 2-phenylethenesulfonamide moieties, which determine the efficacy of its action as hybrid anticancer agent. PSHA was screened for in vitro antiproliferative activity against HeLa and Lewis lung carcinoma (LLC) cancer cells and also examined the PSHA effect on cell cycle progression and its ability to induce apoptosis. The morphological properties as the cell adhesiveness and nuclear-to-cytoplasm ratio (NCR) in HeLa cells were investigated.
Featured Image
Why is it important?
Obtained results demonstrate that our compound can serve as a base for design of novel high-effective antimetastatic and antitumor agent
Perspectives
Writing this article was a great pleasure as it has co-authors with whom I have had long standing collaborations. The results of this article contribute to the development of anti-metastatic drugs, which is no less important, since the metastasis cascade determines the progression and invasion of cancer, ultimately leading to mortality.
Svitlana Orysyk
National Academy of Sciences of Ukraine
Read the Original
This page is a summary of: Novel Hybrid Compound 4-[(E)-2-phenylethenesulfonamido]-N-hydroxybutanamide with Antimetastatic and Cytotoxic Action: Synthesis and Anticancer Screening, Anti-Cancer Agents in Medicinal Chemistry, January 2019, Bentham Science Publishers,
DOI: 10.2174/1871520618666180313151503.
You can read the full text:
Contributors
The following have contributed to this page
